3 views left Get unlimited views with a free account

Take your business to the next level. Explore the latest trends and actionable insights to inform business strategy and pinpoint opportunities and risks.

Number of ongoing Clinical Trials (for drugs) involving Liposarcoma by Phase

Industry: Pharmaceuticals
Current: Other Industry Indicators

There are currently 308 ongoing clinical trials involving Liposarcoma
Of the 308 trials,83 trials are in Phase I
Furthermore, 79 trials are in Phase II

Number of ongoing Clinical Trials (for drugs) involving Liposarcoma by Phase

View as table

The global pharmaceutical industry is steadily developing new drugs for Liposarcoma, an Oncology condition. The largest number of ongoing clinical trials for Liposarcoma is conducted in North America. Asia-Pacific and Europe are among some of the other prominent regions engaged in Liposarcoma-related drug trials.

Memorial Sloan Kettering Cancer Center: The leading ongoing Liposarcoma related clinical trial sponsor

Memorial Sloan Kettering Cancer Center is the top sponsor for Liposarcoma-related ongoing clinical trials.

University of Texas MD Anderson Cancer Center, Sun Yat-sen University, National Cancer Institute US, Adaptimmune Therapeutics Plc, and Fox Chase Cancer Center are among other notable clinical trial sponsors involved in Liposarcoma. A clinical trial sponsor can be a Company, Government, Individual, or Institution.

Marketed Drugs involving Liposarcoma

Eribulin mesylate (E-7389, Halaven) and trabectedin (Yondelis) are among the key marketed drugs involving Liposarcoma.

Eribulin mesylate (E-7389, Halaven) is a microtubule dynamics inhibitor belonging to the halichondrin class of antineoplastic agents. It functions via the Tubulin Inhibitor mechanism of action. It is formulated as a solution for the intravenous route of administration. Halaven is indicated for the treatment of patients with locally advanced or metastatic breast cancer and unresectable or metastatic liposarcoma (leiomyosarcoma) who have received a prior anthracycline-containing regimen. Halaven is also indicated for the treatment of patients with soft tissue sarcoma. Eribulin mesylate was first approved in 2010 and is marketed globally including the US, the UK, Australia, France, Germany, and Japan by Eisai Inc.

Trabectedin (Yondelis) is an anti-tumor agent of marine origin discovered in the Caribbean tunicate, ecteinascidia turbinata. It functions via DNA Synthesis Inhibitor mechanism of action It is formulated as a lyophilized powder for solution for injection for intravenous route of administration. Yondelis is indicated for the treatment of adult patients with advanced soft tissue sarcoma, after the failure of anthracyclines and ifosfamide, or those who are unsuited to receive these agents. Yondelis in combination with pegylated liposomal doxorubicin (PLD) is indicated for the treatment of patients with relapsed platinum-sensitive ovarian cancer. Trabectedin was first approved in 2007 and is marketed globally including the US, the UK, Australia, France, Germany, and Japan by Johnson & Johnson.